Johnson & Johnson (JNJ) reported a 5% year-on-year rise in sales for Q1 sales — though, in a bitter-sweet twist, it's dropped its future forecast.

Though Covid-19 vaccines sales have been good for the company (go figure), it's dropping the single-dose "one and done" vaccines from its future outlook. Their hopes were for this shot to bring in over $3b in sales… bummer.

But as with all good things in life, balance is key. Whilst sales are up, money is dripping from the money here and there. Case in point: it's recently agreed to settle opioid-related claims with West Virginia for $99m.